Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies by Hanker, A. B. et al.
Mutant PIK3CA accelerates HER2-driven transgenic
mammary tumors and induces resistance to
combinations of anti-HER2 therapies
Ariella B. Hankera, Adam D. Pfefferleb, Justin M. Balkoa,c, María Gabriela Kubad, Christian D. Younga, Violeta Sáncheza,
Cammie R. Suttona, Hailing Chenge, Charles M. Peroub,f, Jean J. Zhaoe,g,1, Rebecca S. Cookc,h,2,
and Carlos L. Arteagaa,c,h,1,2
Departments of aMedicine, dPathology, and hCancer Biology and cBreast Cancer Research Program, Vanderbilt–Ingram Cancer Center, Vanderbilt University,
Nashville, TN 37232; Departments of bPathology and Laboratory Medicine and fGenetics, Lineberger Comprehensive Cancer Center, University of North Carolina
at Chapel Hill, Chapel Hill, NC 27599; and Departments of eCancer Biology and gBiological Chemistry and Molecular Pharmacology, Dana-Farber Cancer
Institute, Harvard Medical School, Boston, MA 02115
Edited by Joan S. Brugge, Harvard Medical School, Boston, MA, and approved July 22, 2013 (received for review February 19, 2013)
Human epidermal growth factor receptor 2 (HER2; ERBB2) ampli-
fication and phosphatidylinositol-4,5-bisphosphate 3-kinase, cata-
lytic subunit alpha (PIK3CA) mutations often co-occur in breast
cancer. Aberrant activation of the phosphatidylinositol 3-kinase
(PI3K) pathway has been shown to correlate with a diminished re-
sponse to HER2-directed therapies. We generated a mouse model of
HER2-overexpressing (HER2+), PIK3CAH1047R-mutant breast cancer.
Mice expressing both human HER2 and mutant PIK3CA in the mam-
mary epithelium developed tumors with shorter latencies compared
with mice expressing either oncogene alone. HER2 and mutant
PIK3CA also cooperated to promote lung metastases. By microar-
ray analysis, HER2-driven tumors clustered with luminal breast
cancers, whereas mutant PIK3CA tumors were associated with
claudin-low breast cancers. PIK3CA and HER2+/PIK3CA tumors ex-
pressed elevated transcripts encoding markers of epithelial-to-
mesenchymal transition and stem cells. Cells from HER2+/PIK3CA
tumors more efficiently formed mammospheres and lung metasta-
ses. Finally, HER2+/PIK3CA tumors were resistant to trastuzumab
alone and in combination with lapatinib or pertuzumab. Both drug
resistance and enhanced mammosphere formationwere reversed by
treatment with a PI3K inhibitor. In sum, PIK3CAH1047R accelerates
HER2-mediated breast epithelial transformation and metastatic
progression, alters the intrinsic phenotype of HER2-overexpress-
ing cancers, and generates resistance to approved combinations
of anti-HER2 therapies.
The human epidermal growth factor receptor 2 (HER2) on-cogene, which encodes the HER2 receptor tyrosine kinase, is
amplified in 20% of breast cancers (1). HER2 activation triggers
signal transduction through oncogenic signaling pathways, such
as the PI3K–Akt survival pathway, which is arguably the most
commonly mutated pathway in human cancer. In breast cancer,
hyperactivation of the PI3K pathway can occur through a num-
ber of mechanisms, including activating mutations in phospha-
tidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha
(PIK3CA, the gene encoding the p110α catalytic subunit) (2).
More than 80% of PIK3CA mutations occur in two “hot spots”:
E452K and E545K (exon 9) in the helical domain and H1047R
(exon 20) in the kinase domain. The PI3K–Akt survival pathway
has attracted considerable interest as a target for therapeutic
intervention. Indeed, PI3K inhibitors are currently in clinical
trials for the treatment of breast and other cancers (2).
Approximately 40% of HER2+ breast cancers harbor acti-
vating mutations in PIK3CA (3), consistent with the notion that
these two oncogenes have nonoverlapping functions and may
cooperate to promote tumor growth. In addition, mutant PIK3CA
enhances HER2-mediated transformation of MCF10A breast
epithelial cells in vitro (4). Trastuzumab, an antibody directed
against the ectodomain of HER2, pertuzumab, an antibody that
blocks dimerization of HER2 with other ERBB receptors, and
lapatinib, an ATP-competitive tyrosine kinase inhibitor of EGFR
and HER2, are approved for the treatment of patients with HER2-
overexpressing breast cancer. However, both de novo and acquired
resistance to anti-HER2 therapies are not uncommon (5). Several
studies suggest that PIK3CA mutations confer resistance to these
therapies (6–8), but confirmation of a causal association between
aberrant activation of the PI3K pathway and resistance to
HER2-directed therapies in the clinic is still missing.
To further study the role of PIK3CA mutations in HER2+
breast cancer, we generated a genetically engineered mouse
model expressing human HER2 and PIK3CAH1047R, the
most common PIK3CA mutation found in human breast cancers.
We used this model to determine whether HER2 and PIK3-
CAH1047R cooperate to promote mammary tumor formation and
progression and whether mutant PI3K promotes innate re-
sistance to anti-HER2 therapies in a defined genetic background.
Results
HER2 and Mutant PIK3CA Induce Distinct Premalignant Changes in the
Mammary Gland. To generate a mouse model of human HER2+
/PIK3CA-mutant breast cancer, we crossed mice bearing three
transgenes (Fig. S1A). MMTV-HER2 drives high levels of human
HER2 in the mammary epithelium, resulting in tumor formation
(9). MMTV-rtTA, together with TetOp-HA-PIK3CAH1047R-IRES-
luciferase, allows for the doxycycline (DOX)-inducible expression
of mutant PI3K in the mammary gland (10). For simplicity, we
refer to mice bearing all three oncogenes as HER2+PIK3CA;
mice expressing either oncogene alone are referred to as HER2
or PIK3CA. Starting at 4 wk of age, female mice were treated
with DOX in their drinking water. DOX-induced expression of
luciferase in the mammary glands was observed within 1 wk (Fig.
S1B). Luciferase expression was not detected in the absence of
DOX, or in MMTV-HER2.rtTA mice treated with DOX (Fig. S1B).
We asked first if the HER2 and PIK3CAH1047R transgene
products synergistically transformed mammary epithelial cells.
We performed whole mount staining of mammary glands from
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12-wk-old virgin transgenic mice and found that expression of
HER2 increased ductal side branching, whereas mutant
PI3K increased growth of lobuloalveolar structures (Fig. S2A).
The combined expression of both HER2 and PI3KH1047R
resulted in a combination of both phenotypes, such that side
branching and lobulo-alveolar growth were markedly in-
creased. Immunohistochemistry (IHC) showed elevated levels of
the PI3K target p-AKT and the proliferation marker Ki67 in on-
cogene-expressing glands (Fig. S2 A–C). Terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL) staining
indicated higher rates of apoptosis in PIK3CA-expressing mammary
glands relative to wild type (Fig. S2D). However, the differ-
ences in Ki67 and TUNEL staining between the three onco-
gene-expressing models were not statistically significant.
HER2 and Mutant PIK3CA Accelerate Mammary Tumor Formation and
Lung Metastases. We next treated mice expressing HER2 alone,
PIK3CA alone, or both oncogenes with DOX beginning at 4 wk
of age, and serially palpated mammary glands to detect tumor
formation. In the absence of DOX, rtTA.PIK3CA mice failed
to develop tumors up to 500 d of follow-up (Fig. 1A). HER2-
expressing mice (HER2.rtTA or HER2.PIK3CA +DOX, or unin-
duced HER2.rtTA.PIK3CA –DOX) formed tumors with a median
latency of 368 d (∼12 mo). PIK3CA mice formed tumors with a
median latency of 149 d (∼5 mo), whereas HER2+PIK3CA mice
did so at 76 d (∼2.5 mo) postinduction. This latency period was
significantly shorter than that seen in mice expressing either on-
cogene alone (P = 0.0012 vs. PIK3CA; P < 0.0001 vs. HER2; log-
rank test; Fig. 1A). When corrected for age at time of killing, the
HER2+PIK3CA mice developed significantly more tumors per
mouse, and carried a larger tumor burden, measured as total tu-
mor volume and tumors per mouse (Fig. S3 A and B). In addition,
HER2+PIK3CA tumors grew faster than tumors expressing only
PIK3CA (Fig. S3C). Suggestive of faster growth outpacing tumor
angiogenesis, HER2+PIK3CA tumors and lung metastases were
frequently hemorrhagic (Fig. S3 D–G).
HER2+PIK3CA tumors expressed both HER2 and HA-tagged
p110α by Western blot analysis (Fig. 1B). PIK3CA tumors also
expressed elevated levels of p-AKT and its substrate p-PRAS40,
suggesting that the PI3K pathway is highly activated in these
tumors. All tumors exhibited elevated p-S6 compared with
control mammary glands. Although HER2-expressing tumors
exhibited elevated p-HER3, the HER2+PIK3CA tumors showed
pPRAS40T246
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Fig. 1. HER2 and mutant PIK3CA cooperate to
promote mammary tumor formation and metasta-
sis. (A) Female mice of the indicated genotypes were
continuously administered DOX or vehicle control
beginning at 4 wk of age. Mice were palpated twice
weekly for the presence of mammary tumors. HER2.
rtTA.PIK3CA + DOX tumors that lacked human HER2
or HA-PI3K expression by immunofluorescence were
excluded from analysis. *P = 0.0012; **P < 0.0001,
log-rank test. (B) Mammary glands fromMMTV-rtTA
mice (control) or mammary tumors from HER2+
PIK3CA, PIK3CA, or HER2 mice were snap frozen in
liquid nitrogen, homogenized, and lysed in Nonidet
P-40–containing lysis buffer. Tissue lysates were
subjected to immunoblot analysis with the indicated
antibodies. β-Actin was used as a loading control.
Scans are all from the same gel/film; the vertical
black line indicates an irrelevant lane that was re-
moved from the figure for clarity. (C) FFPE tumor
and lung tissues were subjected to IF with the in-
dicated antibodies. (Scale bar, 50 μm.) White arrows
indicate HER2-expressing cells that fail to express
HA, whereas yellow arrowheads indicate HA-
expressing cells that fail to express human HER2.
The percent overlap refers to the percentage of
green pixels (HER2) that contain red (HA) and vice
versa. (D) Percent overlap of HER2 and HA-PI3K
staining was quantified from immunofluorescent
images of HER2.rtTA.PIK3CA + DOX primary tumors
using MetaMorph software. Data shown are the
average ± SEM **P < 0.01, Student t test. (E and F)
Nude mice (n = 8–10 per group) were injected in the
tail vein with dissociated tumor cells of the indicated
genotypes. Lungs were harvested 32 d later. (E )
Metastases were scored from H&E sections taken
at 50-μm intervals throughout the lungs (13–26
sections per mouse; **P < 0.01, Tukey’s multiple
comparisons test). (F ) Area of lung metastases
was quantifed using LP2 software. Data shown
are the average ± SEM (*P < 0.01; **P < 0.001,
Student t test).











reduced expression of total HER3 in comparison, consistent
with PI3K-mediated feedback repression of HER3 transcrip-
tion (11–13).
We next determined if human HER2 and HA-p110αH1047R
were coexpressed within the same cells in HER2+PIK3CA tumors.
We performed immunofluorescence (IF) of mouse mammary
tumors using trastuzumab as the primary antibody, followed
by a fluorescently conjugated anti-human secondary antibody.
Trastuzumab only recognizes human HER2 and not mouse erbb2.
We costainedwith anHAantibody to detectHA-p110αH1047R.We
observed heterogeneous expression of both transgenes in pri-
mary tumors; surprisingly, not all tumor cells coexpressed both on-
cogene products as measure by IF (Fig. 1C). In contrast, detectable
coexpression was significantly higher in lung metastases (Fig. 1 C
and D), suggesting that high coexpression of both oncogenes
selects for tumor cells with an increased capacity to metastasize.
We further studied the metastatic phenotype of the mammary
tumors. Lung metastases were rare in our original cohort, probably
because these mice were killed when total tumor burden reached
∼1,500 mm3. Therefore, we injected cells isolated from HER2,
PIK3CA, or HER2+PIK3CA tumors in the tail vein of nude mice.
HER2+PIK3CA tumor cells formed significantly more lung metas-
tases than cells from tumors expressing either oncogene alone
(Fig. 1E). The HER2+PIK3CA lung metastases were also sig-
nificantly larger (Fig. 1F and Fig. S3 H–J). These data suggest
that HER2 and PI3KH1047R strongly cooperate to promote
metastatic colonization and growth.
Mutant PIK3CA Confers Features of Epithelial-to-Mesenchymal Transition
and Stem-Like Cells. We next examined the histopathological fea-
tures of tumors expressing HER2, mutant PI3K, or both. HER2-
expressing tumors were histologically homogeneous, consisting
mostly of solid adenocarcinomas. By IHC, they expressed lu-
minal cytokeratin 18 but were negative for the basal markers p63
and cytokeratin 14 (Fig. S4A). In accordance with previous
studies (10), PIK3CA tumors exhibited heterogeneous cancer
histologies, including a large proportion of metaplastic carci-
nomas.HER2+PIK3CA tumors were also heterogeneous, although
the histological spectrum was distinct from PIK3CA-only tumors
(Fig. S4 A and B). Like the PIK3CA tumors, the HER2+PIK3CA
tumors expressed basal and luminal markers (Fig. S4A), suggesting
that these tumors may arise from pluripotent progenitor cells and/
or that mutant PI3K enhances tumor cell plasticity.
Next, we analyzed gene expression using microarrays. Mam-
mary tumors from each genotype (HER2, PIK3CA, or HER2+
PIK3CA) contained distinct clusters of genes, further suggesting
thatHER2+PIK3CA tumors are phenotypically distinct (Fig. S5A).
Tumors from HER2mice treated with or without DOX exhibited
similar gene expression patterns. Microarray data were used to
determine whether these mouse tumors are associated with a
particular subtype of human breast cancer. We derived a gene
signature for each of our models by identifying differentially ex-
pressed genes in comparisonwith a large series ofmousemodels of
breast cancer (14, 15). The average of each signature was scored in
the UNC337 dataset (Fig. 2A) (16) and the combined 855 dataset
(Fig. 2B) (17) of human breast tumors. Like the MMTV-Neu
model, the MMTV-HER2 signature was enriched in the luminal
breast cancer subtype (Fig. 2) (14). In both datasets, the PIK3CA
andHER2+PIK3CA signatures weremost strongly associated with
the claudin-low breast cancer subtype (Fig. 2).
Claudin-low breast cancer is a subtype of triple-negative breast
cancer characterized by poor differentiation, elevated expression
of markers of an epithelial-to-mesenchymal transition (EMT) and
enrichment for cancer stem cells (CSCs). This subtype also shares
similarities with metaplastic breast cancer (16, 18), consistent with
our histological findings. In agreement, gene set analysis (GSA)
showed that gene sets associated with EMT, metastasis, spherical
vs. adherent growth, and metaplastic breast carcinoma, were ele-
vated in the PIK3CA and HER2+PIK3CA expression profiles (Ta-
ble S1 and Fig. S5B). We then used a recently described metric to
calculate a “differentiation score” (D score) (16), with high scores
representing a likeness to mature luminal cells, intermediate scores
to luminal progenitor cells, and low scores to adult mammary stem
cells. Whereas the HER2 tumors were more similar to mature
luminal cells, PIK3CA tumors had intermediate D scores on aver-
age (Fig. S6C), suggesting that cells from PIK3CA tumors are most
similar to luminal progenitors (16).
To further test the association of PIK3CA tumors with the clau-
din-low subtype, we examined ourmicroarray data for expression of
luminal andEMTmarkers and putativemarkers ofmammary stem-
likecells. Fig. 3A shows that expressionof the luminalmarkersXbp1,
Erbb3, and Spdef were reduced in the PIK3CA andHER2+PIK3CA
tumors relative to theHER2 tumors. In addition, the EMTmarkers
Snai1 (Snail), Snai2 (Slug), Twist1, Twist2, Vim (Vimentin), Cdh2
(N-cadherin), and Sparc were elevated in PIK3CA and HER2+
PIK3CA tumors (Fig. 3B). Finally, expression of CSC markers,
including Bmi1, Itgb1 (CD29), Procr, Thy1, and the Notch ligands
Jag1 and Jag2 (19–21) were significantly up-regulated in PIK3CA
and HER2+PIK3CA tumors (Fig. 3C). Consistent with these
results, protein levels of the epithelial cellmarker E-cadherin were
reduced in HER2+PIK3CA tumors relative to HER2 tumors (Fig.
3D). Further, IHC staining of Vimentin and Snail/Slug was ele-
vated in HER2+PIK3CA tumors and lung metastases relative to
corresponding tissues from HER2 transgenics (Fig. S7 A–C).
These results suggest that mutant PIK3CA induces mammary
tumors with EMT and stem-like features.
To further address if mutant PIK3CA tumors are enriched
with CSCs, we harvested primary tumor cells and performed
mammosphere-forming assays. This method is used to measure
the tumor-initiating capacity of cancer cells. HER2+PIK3CA mam-
mosphere cultures retained luciferase expression only in the pres-
ence of DOX (Fig. S8). DOX-treated cells from HER2+PIK3CA
tumors formed significantly more and larger mammospheres
than DOX-minus cells or cells from tumors expressing only HER2
(Fig. 4 A and B). The pan-PI3K inhibitor BKM120 (22) markedly
decreased the ability of HER2+PIK3CA cells to form mammo-
spheres, whereas trastuzumab had no effect on mammosphere
formation (Fig. 4C), further suggesting that aberrant PI3K activity
is associated with CSC characteristics.
Mutant PIK3CA Confers Innate Resistance to Trastuzumab and
Combinations of Anti-HER2 Therapies. We transplanted tumors
from HER2 or HER2+PIK3CA mice into recipient nude mice;
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Fig. 2. Gene expression profiles of PIK3CA and HER2+PIK3CA tumors resemble
the claudin-low subtype of human breast cancer. RNA isolated from mouse
mammary tumors of the indicated genotypes was hybridized to Agilent 4 × 180
k mouse microarrays. Gene signatures were obtained by determining all genes
that were up-regulated or down-regulated in tumors of the shown genotypes
relative to other genetically engineered mouse models of breast cancer (false
discovery rate, 0%). The average of each gene signature was calculated for each
array in the UNC337 dataset (A) or combined 855 dataset (B).
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with PBS or trastuzumab. Treatment with trastuzumab inhibited
growth of HER2-induced but not HER2+PIK3CA tumor trans-
plants (Fig. 5 A and B). We next determined whether these
tumors responded to BKM120, which has currently completed
phase I studies in patients with cancer (23). Treatment with
BKM120 inhibited tumor growth but did not induce tumor re-
gressions. The combination of trastuzumab and BKM120 was
moderately superior to single-agent BKM120, suggesting that in-
hibition of both oncogenes is required to inhibit tumor growth in
this bitransgenic model (Fig. 5C).
We next examined pharmacodynamic biomarkers of target in-
activation by Western blot analysis of tumor lysates and IHC of
formalin-fixed, paraffin embedded (FFPE) tumor sections. BKM120
strongly inhibitedp-AKTS473 andmoremodestlyblockedp-AKTT308
following 18 d of treatment, whereas trastuzumab alone failed to
inhibit p-AKT, p-S6, p-HER3, or p-ERK inHER2+PIK3CA tumors
(Fig. 5D and Fig. S9). In addition, the combination of BKM120 and
trastuzumab decreased vimentin expression, although E-cad-
herin and N-cadherin levels were unchanged (Fig. 5D).HER2+
PIK3CA tumors treated with BKM120 displayed up-regulation
of p-HER3Y1289 and p-ERK, consistent with relief of PI3K-
driven negative repression of HER3 transcription/expression and
ERK signaling (11–13, 24). However, the up-regulation of pERK
did not rescue the inhibition of p-S6. Total HER2 and HA-PI3K
levels remained unchanged with treatment.
We finally examined whether mutant PIK3CA also conferred
resistance to currently approved anti-HER2 combinations,
specifically trastuzumab/lapatinib and trastuzumab/pertuzumab
(25–27). HER2+PIK3CA tumors failed to respond to these com-
binations (Fig. 6A). However, the combination of trastuzumab +
pertuzumab + BKM120 inhibited tumor growth better than
BKM120 alone. There was also a trend toward better inhibition
with trastuzumab + lapatinib + BKM120, but this was not sta-
tistically significant. Likewise, dual HER2 blockade also failed to
inhibit p-AKT or p-S6 (Fig. 6B). The addition of pertuzumab
reduced BKM120-induced up-regulation of p-HER3, but not
p-ERK. Lapatinib + trastuzumab also failed to prevent BKM120-
induced p-ERK, suggesting that dual HER2 blockade does not
prevent feedback compensation upon inhibition of PI3K in these
tumors. Whether the addition of MEK inhibitors will improve
the efficacy of the BKM120-containing combination will require
additional investigation.
Discussion
Resistance to current anti-HER2 therapies is a major hurdle in
the eradication of HER2+ breast cancer. Several studies have
suggested aberrant activation of the PI3K pathway as a mecha-
nism of resistance to anti-HER2 therapies, although confirmation
in the clinic is still unclear. Herein, we uniquely characterized a
genetically engineered mouse mammary tumor model harboring
both (human) HER2 and mutant PIK3CA. We showed that
coexpression of both oncogenes in the mouse mammary gland
accelerated tumor formation with an average tumor latency of
just 2.5 mo following DOX induction. These tumors were his-
tologically heterogeneous, exhibited features of EMT and stem-
like cells, and displayed a high metastatic propensity. HER2+
PIK3CA tumors also were resistant to trastuzumab as a single
agent and in combination with lapatinib or with pertuzumab. Drug
resistance was partially reversed by the PI3K inhibitor BKM120.
We propose that this conditional mouse model will be a useful
tool for testing novel drugs and combinations for the treatment
















Fig. 3. Expression of EMT and CSC markers is increased in PIK3CA and
HER2+PIK3CA tumors, whereas expression of luminal markers is reduced. (A–
C) Relative gene expression of luminal breast cancer markers (A), EMT
markers (B), or CSC markers (C) was quantified from the microarray ex-
pression data described above using GraphPad PRISM software (ANOVA P <
0.05). *P < 0.05, **P < 0.01, ***P < 0.001, Tukey’s multiple comparison test.
(D) Mouse mammary tumor lysates were subjected to immunoblot analysis









































































Fig. 4. Induction of PI3KH1047R promotes mammosphere formation. (A)
Mammospheres were imaged using the 10× objective of an Olympus CK40
microscope. (Scale bar, 100 μm.) (B) Total mammosphere volume from each
well was quantified using Gelcount software on day 13. (C) DOX-treated
HER2+PIK3CA mammospheres were treated with 20 μg/mL trastuzumab,
1 μM BKM120, or the combination. Total mammosphere volume from each
well was quantified using Gelcount software on day 12. Data represent the
average ± SD of three replicate wells. **P < 0.01, Student t test.











HER2 and PI3KH1047R cooperated to promote transformation
of the mammary epithelium, cancer establishment, and metas-
tasis. The mechanism by which these two oncogenes cooperate in
this setting is unclear. Whereas it is possible that HER2 over-
expression may further enhance the activity of mutant PI3K, we
did not observe an increase in phosphorylation of AKT or down-
stream targets in the HER2+PIK3CA mammary glands or tumors
compared with tumors expressing PIK3CA alone (Figs. 1B and
2B). HER2 is also capable of activating the MAPK pathway.
Whereas p-ERK levels were low in HER2 tumors, they were el-
evated in HER2+PIK3CA tumors (Fig. 2B). However, p-ERK levels
were also high in untransformed mammary glands, so the signifi-
cance of elevated MAPK signaling in these tumors is unclear. Table
S2 presents a list of genes that are differentially expressed in the
HER2+PIK3CA tumors compared with the tumors expressing
either oncogene alone; some of these genes may account for the
increased tumorigenicity observed in this model.
The histopathological heterogeneity observed in the PIK3CA
tumors is consistent with other mouse models of PI3K-induced
breast cancer (28), including PIK3CAH1047R knock-in models (29,
30). This heterogeneity also reflects the fact that although
PIK3CA mutations are enriched in the luminal A subtype, they
are found across all subtypes of human breast cancer (3). In-
terestingly, ∼40% of the tumors in our PIK3CA mouse model
were classified as metaplastic carcinomas, consistent with the
high rate of PIK3CA mutations (∼50%) found in human meta-
plastic carcinomas (18). This suggests that PIK3CA-induced tumors
may be useful models for the study of this rare form of breast
cancer. The link with metaplastic breast carcinoma is further
strengthened by the finding that the PIK3CA-driven tumors were
associated with the claudin-low subtype of breast cancer, because
claudin-low and metaplastic breast carcinomas exhibit similar
gene expression patterns (16, 18). Furthermore, we found that the
PIK3CA and HER2+PIK3CA tumors displayed high expression of
EMT and stem cell markers and that induction of PIK3CA pro-
moted mammosphere formation. These data are in agreement
with in vitro studies that have implicated the PI3K pathway in
EMT (31, 32) and stem cell maintenance in breast cancer (33–
35). Therefore, the association between PIK3CA mutations and
the claudin-low subtype of breast cancer, as well as EMT and
stem-like features, suggests that HER2+ breast cancers harbor-
ing PIK3CA mutations will exhibit a more virulent behavior than
HER2+ tumors with wild-type PIK3CA.
Several mechanisms may explain why mutational activation of
PI3K promotes resistance to therapeutic inhibitors of HER2 in
our model system. First, HER2 blockade did not affect p-AKT
levels in the HER2+PIK3CA tumors (Fig. 6B), suggesting that it
can no longer inhibit PI3K signaling in the presence of mutant
PIK3CA. In agreement, a recent study showed that the PI3K
H1047R mutation enhanced lipid binding, basal catalytic activity,
and interaction with the plasma membrane (36) and hence may
be insensitive to dual blockade of HER2 upstream. The receptor-
independent strong catalytic activity of PI3K H1047R is further
supported in our studies by the lack of response of the bigenic
tumors to trastuzumab/lapatinib and transtuzumab/pertuzumab.
Second, HER2+PIK3CA tumors displayed heterogeneous, non-
overlapping expression of HER2 and HA-PI3K transgenes (Fig.
1C); presumably trastuzumab would not inhibit HER2-negative,
HA-PI3K–expressing cancer cells within these heterogeneous
tumors. However, we do not believe that this contributes to tras-
tuzumab resistance in our model, because treatment with trastu-
zumab did not affect HA-PI3K or HER2 expression (Fig. 5D).
Third, both EMT and CSCs may play a role in trastuzumab re-
sistance. The EMT transcription factors Snail and Slug, both
transcriptionally up-regulated in our HER2+PIK3CA tumors (Fig.
3B), were recently shown to confer resistance to trastuzumab in
HER2+ cells (37). CSCs may be less sensitive to trastuzumab
than their more differentiated counterparts (38), and long-
term trastuzumab treatment has been shown to enrich for CSCs
that display an EMT phenotype (39). Indeed, mutant PIK3CA-
containing tumors were associated with increased stem cell
characteristics, such as the ability to form mammospheres in








































































































Fig. 5. HER2+PIK3CA tumors are resistant to trastuzumab, but respond to the
combination of trastuzumab + BKM120. (A and B) Nude mice were trans-
planted with HER2-expressing (A) or HER2+PIK3CA (B) cells harvested from
transgenic tumors. When tumors reached ≥200 mm3, mice were treated with
vehicle or trastuzumab twice per week. Tumors were measured with calipers
twice weekly. (C) Mice transplanted with HER2+PIK3CA tumors were ran-
domized to receive vehicle control, trastuzumab, BKM120, or the combination.
Each data point represents the mean tumor volume in mm3 ± SEM. P values
were calculated by Student t test. *, relative to vehicle control; #, relative to
BKM120. (D) At the study endpoint, HER2+PIK3CA tumors from C were har-
vested and lysed in Nonidet P-40–containing lysis buffer. Lysates were probed















































Fig. 6. HER2+PIK3CA tumors are resistant to dual blockade of HER2. (A) Mice
with established HER2+PIK3CA tumor transplants were randomized to receive
vehicle control, BKM120, trastuzumab + lapatinib ± BKM120 (T + L ± B), or
trastuzumab + pertuzumab ± BKM120 (T + P ± B) as described in SI Materials
andMethods. Eachdatapoint represents themeantumorvolumeinmm3±SEM.
P values were calculated by Student t test. ** or ***, relative to vehicle control;
#, relative to BKM120. (B) Tumor lysates harvested at the study endpoint were
probed with the indicated antibodies. β-Actin was used as a loading control.
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the mammosphere-forming capacity of HER2+PIK3CA cells
(Fig. 4C). Finally, the elevated PI3K activity may counteract
the trastuzumab-induced immune response required for an
antitumor effect (39). One limitation of our mouse model is that it
may not accurately recapitulate the genomic complexity of human
tumors, so these studies should be complemented by future
experiments using patient-derived xenografts. It is possible that
a combination ofmultiplemechanisms contribute to the decreased
sensitivity of HER2+/PIK3CA-mutant tumors to HER2 inhibitors.
In summary, HER2 and mutant PI3K cooperate to promote
mammary tumor establishment and metastatic progression. These
tumors are resistant to trastuzumab and combinations of direct
inhibitors of HER2. Addition of a PI3K inhibitor reversed re-
sistance in these tumors, suggesting that combining anti-HER2
therapies with PI3K inhibitors may be beneficial for the clinical
treatment of HER2+/PIK3CA-mutant breast cancers. We spec-
ulate the addition of MEK inhibitors to this combination may
prevent feedback compensation (Fig. 5D) and potentially elimi-
nate these tumors. We propose that the mouse model presented
here will be a valuable tool to investigate the underlying biology of
HER2+/PI3K-mutant breast cancers and for preclinical testing of
therapeutic strategies against this subtype of breast cancer.
Materials and Methods
MMTV-HER2 (human HER2), MMTV-rtTA, and TetOp-HA-PIK3CA-H1047R-
luciferasemice were described previously (9, 10). All mice were housed in the
Association for Assessment and Accreditation of Laboratory Animal Care
International-approved facilities under Vanderbilt University’s Institutional
Animal Care and Use Committee guidelines in a pathogen-free environ-
ment. Detailed descriptions of animal experiments, drug treatments, IHC, IF,
Western blot analysis, microarray analysis, and the mammosphere assay are
provided in SI Materials and Methods.
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